AMED240517P85000
- 0.15
- 0.000.00%
Amedisys Newsroom
Cantor Fitzgerald: Reiterates Amedisys (AMED.US) rating, adjusted from neutral to neutral, with a target price of $101.00.
Cantor Fitzgerald: Reiterates Amedisys (AMED.US) rating, adjusted from neutral to neutral, with a target price of $101.00.
Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Amedisys with a Neutral and maintains $101 price target.
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Amedisys Inc Releases First-Quarter Supplemental Slides
Amedisys 1Q Adj EPS $1.03 >AMED
Amedisys 1Q Adj EPS $1.03 >AMED
Amedisys Is Maintained at Market Perform by Raymond James
Amedisys Is Maintained at Market Perform by Raymond James
Raymond James Maintains Market Perform on Amedisysto Market Perform
Raymond James analyst John Ransom maintains Amedisys from Market Perform to Market Perform.
Amedisys Acquisition by UnitedHealth Unit Seen to Close Despite Potential DOJ Probe, RBC Says
Amedisys' (AMED) acquisition by UnitedHealth Group's (UNH) Optum unit is expected to be completed despite unconfirmed reports of a possible antitrust investigation by the US Department of Justice, RBC Capital Markets said in a note Monday.
Why Amedisys (AMED) Is a Top Value Stock for the Long-Term
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 8.52% RBC Capital $97 → $100 Maintains Outperform 09/14/2023 9.6% Cantor Fitzgerald $100 → $101
RBC Raises Price Target on Amedisys to $100 From $97 to Reflect UnitedHealth Deal Terms, Keeps Outperform Rating
Amedisys (AMED) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $73 to $101.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)
Oregon Health Authority Reviewing UnitedHealth's Deal to Acquire Amedisys
GLONGHUI, March 20 | American family health and hospice care company Amedisys said on Tuesday that the Oregon Department of Health has begun reviewing UnitedHealth's $3.3 billion acquisition deal. The company said the notice from the state government agency said the review would be completed within 180 days.
Oregon's Health Authority Reviewing UnitedHealth's Acquisition of Amedisys
UPDATE 1-Oregon's Health Authority Reviewing UnitedHealth's Acquisition of Amedisys
Amedisys Acquisition Faces Intense Regulatory Review
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)